Waldenstrom Macroglobulinemia (Macroglobulinemia)

A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.

Also Known As:

Macroglobulinemia; Waldenstrom's Macroglobulinemia; Familial Waldenstrom's Macroglobulinaemia; Lymphoma, Lymphocytic, Plasmacytoid; Primary Macroglobulinemia; Waldenstrom's Macroglobulinaemia; Familial Waldenstrom Macroglobulinaemia; Familial Waldenstroms Macroglobulinaemia; Lymphomas, Lymphoplasmacytoid; Lymphoplasmacytoid Lymphoma; Lymphoplasmacytoid Lymphomas; Macroglobulinaemia, Familial Waldenstrom's; Macroglobulinaemia, Waldenstrom's; Macroglobulinemia, Primary; Macroglobulinemia, Waldenstrom; Macroglobulinemia, Waldenstrom's; Waldenstrom Macroglobulinaemia; Waldenstrom's Macroglobulinaemia, Familial; Waldenstroms Macroglobulinaemia; Waldenstroms Macroglobulinemia; Lymphoma, Lymphoplasmacytoid

Networked: 1896 relevant articles (99 outcomes, 161 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Multiple Myeloma
2.	Lymphoma (Lymphomas)
3.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
4.	Neoplasms (Cancer)
5.	Cryoglobulinemia

Experts

1.	Treon, Steven P: 137 articles (01/2022 - 04/2003)
2.	Ghobrial, Irene M: 71 articles (10/2022 - 11/2003)
3.	Hunter, Zachary R: 59 articles (01/2022 - 03/2005)
4.	Castillo, Jorge J: 55 articles (01/2022 - 07/2014)
5.	Patterson, Christopher J: 52 articles (01/2022 - 03/2005)
6.	Xu, Lian: 49 articles (01/2022 - 12/2004)
7.	Leleu, Xavier: 45 articles (08/2019 - 05/2006)
8.	Gertz, Morie A: 44 articles (10/2022 - 01/2002)
9.	Dimopoulos, Meletios A: 43 articles (11/2022 - 05/2002)
10.	Yang, Guang: 41 articles (01/2022 - 03/2009)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Waldenstrom Macroglobulinemia:

1.	Rituximab (Mabthera)FDA Link 01/20/2005 - "Rituximab is an important therapeutic for Waldenstrom's macroglobulinemia (WM). " 07/01/2011 - "The incorporation of rituximab into various regimens has improved depth of response in Waldenstrom macroglobulinaemia (WM), though the impact of achieving better responses remains to be determined. " 08/01/2011 - "Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen." 08/01/2011 - "This study examined the outcome of 248 Waldenstrom macroglobulinaemia (WM) rituximab-naïve patients who responded to a rituximab-containing regimen. " 10/01/2004 - "Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98)."
2.	fludarabineIBA 02/01/1995 - "Fludarabine is an interesting new salvage agent effective against recurrent/resistant Waldenstrom's macroglobulinemia and should be evaluated in further studies in untreated patients with Fludarabine in monochemotherapy or in combination with other active modalities." 03/01/1994 - "2chlorodeoxyadenosine may be effective in patients with Waldenström macroglobulinemia sensitive to fludarabine. " 04/01/2003 - "We report an update on a prospective observational trial for Waldenstrom's macroglobulinemia (WM) that called for re-registration to treatment with fludarabine (30 mg/m(2)) upon the development of symptomatic or progressive disease. " 01/01/1994 - "Subsequent clinical trials have also demonstrated major activity with fludarabine in Waldenstrom's macroglobulinemia. " 06/01/2013 - "Fludarabine in Waldenstrom's macroglobulinemia."
3.	ibrutinibIBA 01/01/2017 - "Although ibrutinib is highly effective in Waldenstrom macroglobulinemia (WM), no complete remissions in WM patients treated with ibrutinib have been reported to date. " 01/01/2022 - "Herein, we present the final report of a single-center, prospective phase II study evaluating ibrutinib 420 mg once daily in 30 treatment-naive patients with Waldenstrom macroglobulinemia (WM). " 11/01/2021 - "Translation of PK/PD attributes into clinical effects was demonstrated in a randomized, phase 3 head-to-head study comparing it with ibrutinib in patients with Waldenström macroglobulinemia.Expert" 12/08/2020 - "Patients with Waldenström macroglobulinemia (WM) lacking activating mutations in the MYD88 gene (MYD88WT) have demonstrated relatively poor outcomes to ibrutinib monotherapy, with no major responses reported in a phase 2 pivotal study. " 06/01/2020 - "Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials."
4.	Dexamethasone (Maxidex)FDA LinkGeneric 02/01/1988 - "We conclude that high dose dexamethasone may offer significant benefits in the treatment of Waldenstrom's macroglobulinemia." 01/01/2013 - "To evaluate the efficacy of one intravitreal injection of dexamethasone (Ozurdex(®); Allergan, Inc., Irvine, Calif., USA) in serous macular detachment (SMD) of one eye, associated with bilateral central retinal vein occlusion (CRVO) in a patient affected by Waldenström's macroglobulinemia (WM). " 12/01/2017 - "This retrospective study was designed to determine the efficacy and safety of low-dose bortezomib and dexamethasone (lBD) in elderly Chinese patients with Waldenstrӧm macroglobulinemia (WM). " 11/01/2017 - "A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone." 12/01/2017 - "Low-dose bortezomib and dexamethasone as primary therapy in elderly patients with Waldenstrӧm macroglobulinemia."
5.	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/01/2005 - "Cutaneous Waldenstrom's macroglobulinemia with "deck-chair" sign treated with cyclophosphamide." 01/01/2023 - "An 80-year-old man diagnosed with primary macroglobulinemia 7 years earlier had been treated with cyclophosphamide, following which he developed dyspnea on exertion. " 01/01/1968 - "[Macrocellular reticulum cell sarcoma as late clinical stage of an endoxan-treated Waldenström's macroglobulinemia]." 04/01/1996 - "Mucinous (colloid) carcinoma of urinary bladder following long-term cyclophosphamide therapy for Waldenstrom's macroglobulinemia." 12/01/1991 - "We report a case of upper urothelial tumor in a patient who had previously received prolonged cyclophosphamide therapy for Waldeström's macroglobulinemia. "
6.	Cladribine FDA LinkGeneric 07/01/2000 - "The aim of the study was to evaluate the results of treatment of Waldenström's Macroglobulinemia with 2-chlorodeoxyadenosine. " 04/01/2003 - "2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia." 07/01/2000 - "2-Chlorodeoxyadenosine treatment of Waldenström's macroglobulinemia--the analysis of own experience and the review of literature." 07/01/1999 - "Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia." 12/01/1998 - "This phase II clinical trial evaluated bolus cladribine as a single agent in Waldenstrom macroglobulinaemia (WM). "
7.	Bortezomib (Velcade)FDA Link 04/01/2009 - "This report provides an update on biological studies and clinical efforts to develop bortezomib as a new treatment of Waldenstrom's macroglobulinemia." 06/01/2007 - "Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248." 04/20/2007 - "Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group." 12/13/2018 - "Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients." 08/01/2015 - "Successful treatment of refractory cold hemagglutinemia in MYD88 L265P mutation-negative Waldenström's macroglobulinemia with bortezomib."
8.	Bendamustine Hydrochloride FDA Link 03/19/2023 - "BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom's Macroglobulinemia." 02/01/2011 - "We report the treatment outcome for 30 relapsed/refractory Waldenström's macroglobulinemia (WM) patients following bendamustine-containing therapy. " 02/01/2011 - "Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia." 10/12/2017 - "A case of Waldenstrom Macroglobulinemia in which intermittent one-day administration cycles of bendamustine were effective for alleviation of nausea and maintenance of remission." 01/01/2015 - "According to the European Society for Medical Oncology and National Comprehensive Cancer Network guidelines on Waldenström macroglobulinemia, bendamustine (B) may be considered a suitable therapeutic option. "
9.	Agammaglobulinaemia Tyrosine KinaseIBA 10/01/2023 - "Advances in genetic and cell signaling studies have resulted in the approval of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia. " 12/14/2021 - "Objective: This study aimed to summarize the clinical characteristics and prognosis of 108 patients with Waldenström macroglobulinemia (WM) in a single center and compare them with those of the Pivotal study with Bruton's tyrosine kinase inhibitor (BTKi) monotherapy. " 06/14/2023 - "[The efficacy and safety of Bruton tyrosine kinase inhibitors as monotherapy in the treatment of newly diagnosed patients with Waldenström macroglobulinemia]." 01/01/2023 - "Bruton tyrosine kinase (BTK) inhibitors have taken a central role in the management of patients with Waldenström macroglobulinemia and are the only agents approved by the Food and Drug Administration (FDA) to treat these patients. " 01/01/2023 - "Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia."
10.	Immunoglobulin M (IgM)IBA 01/01/2016 - "Recent molecular studies have identified mutations in the MYD88 and CXCR4 genes as early events in the pathogenesis of IgM MGUS and Waldenström's macroglobulinemia. " 01/01/2005 - "As a young physician, I encountered a patient with Waldenström's macroglobulinemia, and this inspired me to study the structure of IgM. " 08/01/2000 - "Study of IgM aggregation in serum of patients with macroglobulinemia." 09/01/2023 - "Waldenstrom macroglobulinemia (WM), a rare malignant disorder, occurs as a result of abnormal proliferation of lymphocytes that produce immunoglobulin M. " 07/01/2023 - "Previously, the p.L265P mutation in the MYD88 gene, which is frequently detected in Waldenström macroglobulinemia (WM) with IgM gammopathy, was identified in several cases of SchS. "

Therapies and Procedures

1.	Therapeutics 02/01/1988 - "We examined the efficacy of high dose glucocorticosteroids in two patients with Waldenstrom's macroglobulinemia resistant to other forms of therapy. " 03/01/2023 - "Recent advances in the understanding of Waldenström macroglobulinemia (WM) biology have impacted the development of effective novel agents and improved our knowledge of how the genomic background of WM may influence selection of therapy. " 01/01/2022 - "SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia." 01/01/2015 - "A treatment algorithm based on Mayo Stratification for Macroglobulinemia and Risk-Adapted Therapy (mSMART) and a comparison of important clinical trials in WM is provided. " 07/01/2001 - "Current information on Waldenström macroglobulinemia (WM) is based on retrospective or single-institution studies of patients requiring therapy. "
2.	Drug Therapy (Chemotherapy) 01/01/1979 - "[An atypical form of Waldenstrom's macroglobulinaemia with complete remission lasting for more than two years after multiple chemotherapy (author's transl)]." 07/01/2015 - "He had previously developed primary macroglobulinemia, which had been completely cured by chemotherapy. " 08/01/2023 - "Despite substantial progress in the clinical management of Waldenström's Macroglobulinemia (WM) and the emergence of chemotherapy-free approaches such as BTK inhibitors, WM is still a disease in which current treatments fail to cure and are in part associated with significant toxicities, compromising treatment outcome and quality of life. " 01/01/2019 - "We report a case of 76-year-old-male patient with a history of Waldenström macroglobulinemia diagnosed in 2010 and treated with infusion chemotherapy. " 01/01/2019 - "For this Surveillance, Epidemiology, and End Results (SEER)-Medicare cohort study, we identified 9395 patients with iNHL (follicular, marginal zone, Waldenström macroglobulinemia) treated with chemotherapy from 2006 to 2013. "
3.	Stem Cell Transplantation 05/01/2007 - "Autologous stem cell transplantation as part of first-line treatment of Waldenström's macroglobulinemia." 07/01/2020 - "The role of stem cell transplantation (SCT) for patients with Waldenström's macroglobulinemia (WM) remains undetermined. " 09/01/2019 - "Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia." 01/01/2016 - "The role of stem cell transplantation in Waldenstrom's macroglobulinemia." 02/01/2011 - "Autologous stem cell transplantation as a care option in Waldenström's macroglobulinemia."
4.	Plasmapheresis 04/01/2013 - "Despite the absence of randomized trials, plasmapheresis has consistently demonstrated efficacy in treatment of Waldenström's macroglobulinemia (WM) patients with hyperviscosity syndrome (HVS). " 04/01/1962 - "Metabolic balance study of plasmapheresis in a case of Waldenstrom's macroglobulinemia." 01/01/2021 - "Multimodal Imaging of Waldenstrom Macroglobulinemia-Associated Hyperviscosity-Related Retinopathy Treated with Plasmapheresis." 04/01/2013 - "Role of plasmapheresis in Waldenström's macroglobulinemia." 03/01/2009 - "Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström's macroglobulinemia."
5.	Immunotherapy 01/01/2023 - "Molecular remission is an independent predictor of progression-free survival in patients with Waldenström macroglobulinemia treated with chemo-immunotherapy: Results from the FIL_BIOWM study." 01/01/2020 - "Waldenstrom's macroglobulinemia in the era of immunotherapy." 05/01/2001 - "CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia." 05/01/2001 - "CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia." 12/01/2020 - "Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies."